Benzinga · Aug 18, 2026
HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.
NASDAQ · TRAW
Traws Pharma, Inc.
Healthcare · Biotechnology
$0.52
Down-$0.05 (-9.62%)
Updated Oct 7, 2026, 8:14 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.11M
- P/E ratio
- -1.49
- Dividend yield
- 0.00%
- 52-week range
- $0.43 – $3.23
- Volume
- 125.05K
- Avg. volume
- 327.26K
Price performance · TRAW
TRAW price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
TRAW closed at $0.52 after 21 trading sessions, down 5.88% for the selected period.
- Last close
- $0.52
- Period change
- -5.88%
- Period low
- $0.49
- Period high
- $0.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.5345 | $0.535 | $0.5183 | $0.52 | 125.05K |
| Oct 5, 2026 | $0.556 | $0.5793 | $0.53 | $0.536 | 161.49K |
| Oct 2, 2026 | $0.56 | $0.57 | $0.5501 | $0.5685 | 69.63K |
| Oct 1, 2026 | $0.60 | $0.60 | $0.5373 | $0.5453 | 140.68K |
| Sep 30, 2026 | $0.63 | $0.6849 | $0.59 | $0.5938 | 332.22K |
| Sep 29, 2026 | $0.562 | $0.63 | $0.5423 | $0.626 | 391.86K |
| Sep 28, 2026 | $0.5288 | $0.5899 | $0.5287 | $0.579 | 175.57K |
| Sep 25, 2026 | $0.526 | $0.57 | $0.512 | $0.5632 | 885.76K |
| Sep 24, 2026 | $0.51 | $0.6989 | $0.4966 | $0.56 | 28.31M |
| Sep 23, 2026 | $0.491 | $0.5036 | $0.4825 | $0.5036 | 41.43K |
| Sep 22, 2026 | $0.492 | $0.5175 | $0.49 | $0.50 | 109.13K |
| Sep 21, 2026 | $0.49 | $0.5194 | $0.48 | $0.4998 | 128.2K |
| Sep 18, 2026 | $0.5421 | $0.55 | $0.4818 | $0.49 | 193.79K |
| Sep 17, 2026 | $0.5327 | $0.5498 | $0.5228 | $0.5355 | 79.64K |
| Sep 16, 2026 | $0.529 | $0.5418 | $0.5161 | $0.5332 | 42.36K |
| Sep 15, 2026 | $0.5234 | $0.5466 | $0.5155 | $0.529 | 33.56K |
| Sep 14, 2026 | $0.579 | $0.594 | $0.5159 | $0.5189 | 155.7K |
| Sep 11, 2026 | $0.5301 | $0.5896 | $0.5231 | $0.5643 | 84.47K |
| Sep 10, 2026 | $0.54 | $0.5446 | $0.53 | $0.5315 | 39.03K |
| Sep 9, 2026 | $0.55 | $0.5641 | $0.537 | $0.54 | 179.14K |
| Sep 8, 2026 | $0.56 | $0.59 | $0.5514 | $0.5525 | 50.11K |
Latest TRAW news
The latest Smart Investors Daily articles mentioning TRAW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TRAW research
Overview
Company profile and research snapshot.
Company profile
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 15, 2026 | Ladenburg Thalmann | Neutral | — |
| May 20, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 3, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the
Benzinga · Jul 1, 2026
Traws PharmaFiles Prospectus For Mixed Shelf Offering Of Up To ~$139.2M
Traws Pharma, Inc. $139,185,641.25 Common StockPreferred StockDebt SecuritiesWarrantsUnits This prospectus covers our offer and sale from time to time of any combination of common stock, preferred stock, debt
Yahoo · Jun 22, 2026
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceedNEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that an updated toxicology data package is in the process of being developed in response to information requirements from the United Kingdom’s Medic
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
